Efficacy and Safety of JAK Inhibitors in Rheumatoid Arthritis: Update for the Practising Clinician

The registrational clinical trials and registry data of JAK inhibitors did not identify a difference in the risk of major adverse cardiovascular events, venous thromboembolism, malignancies or infections with a JAK inhibitor versus a biologic DMARD.